Videos

Do-Youn Oh, MD reviews the updated OS results of the phase 3 study, TOPAZ-1, evaluating the use of durvalumab plus GemCis versus placebo for patients with advanced biliary tract cancer (BTC).

Updated Overall Survival from the Phase 3 TOPAZ-1 Study of Durvalumab or Placebo plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer

Do-Youn Oh, MD, PhD, professor, Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, South Korea, discusses the results of the phase 3 TOPAZ-1 trial (NCT03875235) in advanced biliary tract cancer (BTC).

During the 2022 Gastrointestinal Cancers Symposium, the results of the TOPAZ-1 trial were presented. The findings demonstrated a significantly improved overall survival with durvalumab (Imfinzi) in combination with gemcitabine/cisplatin vs placebo plus chemotherapy when used as frontline therapy in patients with advanced BTC. Moreover, the immunotherapy-containing regimen led to a 20% reduction in the risk of death compared with the placebo-containing regimen, Oh says.

Moreover, other end points, such as progression-free survival and objective response rate were improved with durvalumab/chemotherapy vs placebo/chemotherapy in this patient population, Oh explains.

Regarding safety, the frequency of adverse effects was similar between arms, suggesting that most toxicities were related to the chemotherapeutic agents, Oh concludes.

Do-Youn Oh, MD, PhD, discusses the results of the phase 3 TOPAZ-1 trial in advanced biliary tract cancer. 



Do-Youn Oh, MD, PhD

Articles

Updated Overall Survival from the Phase 3 TOPAZ-1 Study of Durvalumab or Placebo plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer

Dr. Oh on the Results of the TOPAZ-1 Trial in Advanced Biliary Tract Cancer